References
- Adams, T. D., A. M. Stroup, R. E. Gress, K. F. Adams, E. E. Calle, S. C. Smith, R. Chad Halverson, S. C. Simper, P. N. Hopkins, and S. C. Hunt. 2009. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring, Md.) 17 (4):796–802. doi:https://doi.org/10.1038/oby.2008.610.
- Anveden, Å., M. Taube, M. Peltonen, P. Jacobson, J. C. Andersson-Assarsson, K. Sjöholm, P.-A. Svensson, and M. S. C. Lena. 2017. Long-term incidence of female-specific cancer after bariatric surgery or usual care in the Swedish obese subjects study. Gynecologic Oncol 145 (2):224–29. doi:https://doi.org/10.1016/j.ygyno.2017.02.036.
- Arnold, M., M. Leitzmann, H. Freisling, F. Bray, I. Romieu, A. Renehan, and I. Soerjomataram. 2016. Obesity and cancer: an update of the global impact. Cancer Epidemiol 41 (April):8–15. doi:https://doi.org/10.1016/j.canep.2016.01.003.
- Bandera, E. V., V. S. Lee, B. Qin, R.-R. Lorna, C. B. Powell, and L. H. Kushi. 2017. Impact of body mass index on ovarian cancer survival varies by stage. Br J Cancer 117 (2):282–89. doi:https://doi.org/10.1038/bjc.2017.162.
- Bergom, C., T. Kelly, M. Bedi, H. Saeed, P. Prior, L. E. Rein, J. F. W. Aniko Szabo, A. D. Currey, and J. White. 2016. Association of locoregional control with high body mass index in women undergoing breast conservation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 96 (1):65–71. doi:https://doi.org/10.1016/j.ijrobp.2016.04.020.
- Bethel, M. A., R. A. Patel, P. Merrill, Y. Lokhnygina, J. B. Buse, R. J. Mentz, N. J. Pagidipati et al. 2018. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 6(2):105–13. doi:https://doi.org/10.1016/S2213-8587(17)30412-6.
- Bhaskaran, K., I. Douglas, H. Forbes, I. dos-Santos-Silva, D. A. Leon, and L. Smeeth. 2014. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet (London, England) 384 (9945):755–65. doi:https://doi.org/10.1016/S0140-6736(14)60892-8.
- Bohula, E. A., S. D. Wiviott, D. K. McGuire, S. E. Inzucchi, J. Kuder, I. KyungAh, C. L. Fanola, A. Qamar, C. Brown, A. Budaj et al. 2018. Cardiovascular safety of lorcaserin in overweight or obese patients. New Engl J Med. 379(12):1107–17. doi:https://doi.org/10.1056/NEJMoa1808721.
- Bulun, S. E., D. Chen, I. Moy, D. C. Brooks, and H. Zhao. 2012. Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab TEM 23 (2):83–89. doi:https://doi.org/10.1016/j.tem.2011.10.003.
- Byers, T., and R. L. Sedjo. 2011. Does intentional weight loss reduce cancer risk? Diabetes Obesity Metab 13 (12):1063–72. doi:https://doi.org/10.1111/j.1463-1326.2011.01464.x.
- Calle, E. E., C. Rodriguez, K. Walker-Thurmond, and M. J. Thun. 2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New Engl J Med 348 (17):1625–38. doi:https://doi.org/10.1056/NEJMoa021423.
- Calle, E. E., and R. Kaaks. 2004. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4 (8):579–91. doi:https://doi.org/10.1038/nrc1408.
- Chlebowski, R. T., and M. M. Reeves. 2016. Weight loss randomized intervention trials in female cancer survivors. J Clin Oncol Off J Am Soc Clin Oncol 34 (35):4238–48. doi:https://doi.org/10.1200/JCO.2016.69.4026.
- Chlebowski, R. T., A. K. Aragaki, G. L. Anderson, M. S. Simon, J. E. Manson, M. L. Neuhouser, K. Pan et al. 2018. Association of low-fat dietary pattern with breast cancer overall survival: a secondary analysis of the women’s health initiative randomized clinical trial. JAMA Oncol. 4(10):e181212. doi:https://doi.org/10.1001/jamaoncol.2018.1212.
- Chlebowski, R. T., J. Luo, G. L. Anderson, W. Barrington, K. Reding, M. S. Simon, J. E. Manson, T. E. Rohan, J. Wactawski-Wende, D. Lane et al. 2019. Weight loss and breast cancer incidence in postmenopausal women. Cancer. 125(2):205–12. doi:https://doi.org/10.1002/cncr.31687.
- de Andrade Mesquita, L., G. Fagundes Piccoli, G. R. da Natividade, B. Frison Spiazzi, V. Colpani, and F. Gerchman. 2021. Is lorcaserin really associated with increased risk of cancer? A systematic review and meta-analysis. Obesity Rev Off J Int Assoc Study Obesity 22 (3):e13170. doi:https://doi.org/10.1111/obr.13170.
- Demark-Wahnefried, W., L. W. Jones, D. C. Snyder, R. J. Sloane, G. G. Kimmick, D. C. Hughes, H. J. Badr, P. E. Miller, L. E. Burke, and I. M. Lipkus. 2014. Daughters and mothers against breast cancer (DAMES): main outcomes of a randomized controlled trial of weight loss in overweight mothers with breast cancer and their overweight daughters. Cancer 120 (16):2522–34. doi:https://doi.org/10.1002/cncr.28761.
- Eakin, E. G., M. M. Reeves, A. D. Goode, E. A. H. Winkler, J. L. Vardy, F. Boyle, M. R. Haas, J. E. Hiller, G. D. Mishra, M. Jefford et al. 2020. Translating research into practice: outcomes from the healthy living after cancer partnership project. BMC Cancer. 20(1):963. doi:https://doi.org/10.1186/s12885-020-07454-4.
- Engmann, N. J., M. K. Golmakani, D. L. Miglioretti, B. L. Sprague, and K. Kerlikowske. 2017. Population-attributable risk proportion of clinical risk factors for breast cancer. JAMA Oncol 3 (9):1228–36. doi:https://doi.org/10.1001/jamaoncol.2016.6326.
- Ewertz, M., M.-B. Jensen, K. Á Gunnarsdóttir, I. Højris, E. H. Jakobsen, D. Nielsen, L. E. Stenbygaard, U. B. Tange, and S. Cold. 2011. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 29 (1):25–31. doi:https://doi.org/10.1200/JCO.2010.29.7614.
- FDA. 2020. “FDA requests the withdrawal of the weight-loss drug belviq, belviq XR (Lorcaserin) from the market.” https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market.
- Flavin, R., S. Peluso, P. L. Nguyen, and M. Loda. 2010. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol (London, England) 6 (4):551–62. doi:https://doi.org/10.2217/fon.10.11.
- Flegal, K. M., D. Kruszon-Moran, M. D. Carroll, C. D. Fryar, and C. L. Ogden. 2016. Trends in obesity among adults in the United States, 2005 to 2014. Jama 315 (21):2284–91. doi:https://doi.org/10.1001/jama.2016.6458.
- The GBD 2015 Obesity Collaborators. 2017. Health effects of overweight and obesity in 195 countries over 25 years. New Engl J Med 377(1):13–27. doi:https://doi.org/10.1056/NEJMoa1614362.
- Goodwin, P. J. 2016. Obesity and breast cancer outcomes: how much evidence is needed to change practice? J Clin Oncol Off J Am Soc Clin Oncol United States 34 (7):646–48. doi:https://doi.org/10.1200/JCO.2015.64.7503.
- Green, J., B. J. Cairns, D. Casabonne, F. L. Wright, G. Reeves, and V. Beral. 2011. Height and cancer incidence in the million women study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncol 12 (8):785–94. doi:https://doi.org/10.1016/S1470-2045(11)70154-1.
- Greenlee, H. A., K. D. Crew, J. M. Mata, P. S. McKinley, A. G. Rundle, W. Zhang, Y. Liao, W. Y. Tsai, and D. L. Hershman. 2013. A pilot randomized controlled trial of a commercial diet and exercise weight loss program in minority breast cancer survivors. Obesity (Silver Spring, Md.) 21 (1):65–76. doi:https://doi.org/10.1002/oby.20245.
- Griggs, J. J., P. B. Mangu, S. Temin, and G. H. Lyman. 2012. Appropriate chemotherapy dosing for obese adult patients with cancer: American society of clinical oncology clinical practice guideline. J Oncol Pract 8 (4):e59–61. doi:https://doi.org/10.1200/JOP.2012.000623.
- Halpern, B., and A. Halpern. 2015a. Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications. Expert Opin Drug Saf 14 (2):305–15. doi:https://doi.org/10.1517/14740338.2015.994502.
- Halpern, B., and A. Halpern. 2015b. Why are anti-obesity drugs stigmatized? Expert Opin Drug Saf Engl 14 (2):185–89. doi:https://doi.org/10.1517/14740338.2015.995088.
- Halpern, B., and M. C. Mancini. 2020. Should the same safety scrutiny of antiobesity medications be applied to other chronic usage drugs?. Obesity (Silver Spring. Md.) 28 (7):1171–72. doi:https://doi.org/10.1002/oby.22810.
- Harrigan, M., B. Cartmel, E. Loftfield, T. Sanft, A. B. Chagpar, Y. Zhou, M. Playdon, F. Li, and M. L. Irwin. 2016. Randomized trial comparing telephone versus in-person weight loss counseling on body composition and circulating biomarkers in women treated for breast cancer: the lifestyle, exercise, and nutrition (LEAN) study. J Clin Oncol Off J Am Soc Clin Oncol 34 (7):669–76. doi:https://doi.org/10.1200/JCO.2015.61.6375.
- Harvie, M., M. Pegington, D. McMullan, N. Bundred, K. Livingstone, A. Campbell, J. Wolstenholme et al. 2019. The Effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial. Br J Cancer. 121(6):443–54. doi:https://doi.org/10.1038/s41416-019-0522-6.
- Hawkes, A. L., M. Quinn, V. Gebski, J. Armes, D. Brennan, M. Janda, and A. Obermair. 2014. Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (FeMME) trial. Contemp Clin Trials 39 (1):14–21. doi:https://doi.org/10.1016/j.cct.2014.06.014.
- Hong, J.-L., C. R. Meier, R. S. Sandler, S. S. Jick, and T. Stürmer. 2013. Risk of colorectal cancer after initiation of orlistat: matched cohort study. BMJ (Clin Res Ed.) 347 (August):f5039. doi:https://doi.org/10.1136/bmj.f5039.
- Inoue, M., and S. Tsugane. 2012. Insulin resistance and cancer: epidemiological evidence. Endocr Rel Cancer 19 (5):F1–8. doi:https://doi.org/10.1530/ERC-12-0142.
- Jastreboff, A. M., C. M. Kotz, S. Kahan, A. S. Kelly, and S. B. Heymsfield. 2019. Obesity as a disease: the obesity society 2018 position statement. Obesity 27 (1):7–9. doi:https://doi.org/10.1002/oby.22378.
- Karatas, F., G. Umut Erdem, S. Sahin, A. Aytekin, D. Yuce, A. R. Sever, T. Babacan, O. Ates, Y. Ozisik, and K. Altundag. 2017. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients. Breast (Edinburgh, Scotland) 32 (April):237–44. doi:https://doi.org/10.1016/j.breast.2016.05.013.
- Khandekar, M. J., P. Cohen, and B. M. Spiegelman. 2011. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer Engl 11 (12):886–95. doi:https://doi.org/10.1038/nrc3174.
- Kitson, S., N. Ryan, M. L. MacKintosh, R. Edmondson, J. Mn Duffy, and E. J. Crosbie. 2018. Interventions for weight reduction in obesity to improve survival in women with endometrial cancer. Cochrane Database Syst Rev 2 (2):CD012513. doi:https://doi.org/10.1002/14651858.CD012513.pub2.
- Knowler, W. C., E. Barrett-Connor, S. E. Fowler, R. F. Hamman, J. M. Lachin, E. A. Walker, and D. M. Nathan. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 346 (6):393–403. doi:https://doi.org/10.1056/NEJMoa012512.
- Lauby-Secretan, B., C. Scoccianti, D. Loomis, Y. Grosse, F. Bianchini, and K. Straif. 2016. Body fatness and cancer — viewpoint of the IARC working group. New Engl J Med 375 (8):794–98. doi:https://doi.org/10.1056/NEJMsr1606602.
- Lee, K., L. Kruper, C. M. Dieli-Conwright, and J. E. Mortimer. 2019. The impact of obesity on breast cancer diagnosis and treatment. Curr Oncol Rep 21 (5):41. doi:https://doi.org/10.1007/s11912-019-0787-1.
- Lee, C. G., B. Heckman-Stoddard, D. Dabelea, K. M. Gadde, D. Ehrmann, L. Ford, P. Prorok, E. J. Boyko, X. Pi-Sunyer, A. Wallia et al. 2021. Effect of metformin and lifestyle interventions on mortality in the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care. 44(12):2775–82. doi:https://doi.org/10.2337/dc21-1046.
- Ligibel, J. A., C. M. Alfano, K. S. Courneya, W. Demark-Wahnefried, R. A. Burger, R. T. Chlebowski, C. J. Fabian, A. Gucalp, D. L. Hershman, M. M. Hudson et al. 2014. American society of clinical oncology position statement on obesity and cancer. J Clin Oncol Off J Am Soc Clin Oncol. 32(31):3568–74. doi:https://doi.org/10.1200/JCO.2014.58.4680.
- Lovrics, O., J. Butt, Y. Lee, P. Lovrics, V. Boudreau, M. Anvari, D. Hong, and A. G. Doumouras. 2021. The effect of bariatric surgery on breast cancer incidence and characteristics: a meta-analysis and systematic review. Am J Surg 222 (4):715–22. doi:https://doi.org/10.1016/j.amjsurg.2021.03.016.
- Luo, J., R. T. Chlebowski, M. Hendryx, T. Rohan, J. Wactawski-Wende, C. A. Thomson, A. S. Felix, C. Chen, W. Barrington, M. Coday et al. 2017. Intentional weight loss and endometrial cancer risk. J Clin Oncol Off J Am Soc Clin Oncol. 35(11):1189–93. doi:https://doi.org/10.1200/JCO.2016.70.5822.
- Luo, J., M. Hendryx, J. E. Manson, J. C. Figueiredo, E. S. LeBlanc, W. Barrington, T. E. Rohan, B. V. Howard, K. Reding, G. Y. Ho et al. 2019. Int weight loss and obesity-related cancer risk. JNCI Cancer Spectr. 3(4):kz054. doi:https://doi.org/10.1093/jncics/pkz054.
- Neuhouser, M. L., A. K. Aragaki, R. L. Prentice, J. E. Manson, R. Chlebowski, C. L. Carty, H. M. Ochs-Balcom, C. A. Thomson, B. J. Caan, L. F. Tinker et al. 2015. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women’s health initiative randomized clinical trials. JAMA Oncol. 1(5):611–21. doi:https://doi.org/10.1001/jamaoncol.2015.1546.
- Olsen, C. M., C. M. Nagle, D. C. Whiteman, R. Ness, C. Leigh Pearce, M. C. Pike, M. Anne Rossing, K. L. Terry, A. H. Wu, _. _ et al. 2013. Obesity and risk of ovarian cancer subtypes: evidence from the ovarian cancer association consortium. Endocr Rel Cancer. 20(2):251–62. doi:https://doi.org/10.1530/ERC-12-0395.
- Onstad, M. A., R. E. Schmandt, and K. H. Lu. 2016. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol Off J Am Soc Clin Oncol 34 (35):4225–30. doi:https://doi.org/10.1200/JCO.2016.69.4638.
- Pearce, C. L., D. O. Stram, R. B. Ness, D. A. Stram, L. D. Roman, C. Templeman, A. W. Lee, U. Menon, P. A. Fasching, J. N. McAlpine et al. 2015. Population distribution of lifetime risk of ovarian cancer in the United States. Cancer Epidemiol Biomarkers Prev. 24(4):671 LP–76. doi:https://doi.org/10.1158/1055-9965.EPI-14-1128.
- Pfeiler, G., R. Königsberg, C. Fesl, B. Mlineritsch, H. Stoeger, C. F. Singer, S. Pöstlberger et al. 2011. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol Off J Am Soc Clin Oncol. 29(19):2653–59. doi:https://doi.org/10.1200/JCO.2010.33.2585.
- Pi-Sunyer, X., A. Astrup, K. Fujioka, F. Greenway, A. Halpern, M. Krempf, D. C. W. Lau et al. 2015. A randomized, controlled trial of 3.0 Mg of liraglutide in weight management. New Engl J Med. 373(1):11–22. doi:https://doi.org/10.1056/NEJMoa1411892.
- Piccoli, G. F., L. A. Mesquita, C. Stein, M. Aziz, M. Zoldan, N. A. H. Degobi, B. F. Spiazzi, G. L. Lopes Junior, V. Colpani, and F. Gerchman. 2021. Do GLP-1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis. J Clin Endocrinol Metab 106 (3):912–21. doi:https://doi.org/10.1210/clinem/dgaa891.
- Purcell, S. A., S. A. Elliott, C. H. Kroenke, M. B. Sawyer, and C. M. Prado. 2016. Impact of body weight and body composition on ovarian cancer prognosis. Curr Oncol Rep 18 (2):8. doi:https://doi.org/10.1007/s11912-015-0488-3.
- Renehan, A. G., M. Zwahlen, and M. Egger. 2015. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer 15 (8):484–98. doi:https://doi.org/10.1038/nrc3967.
- Rock, C. L., S. W. Flatt, T. E. Byers, G. A. Colditz, W. Demark-Wahnefried, P. A. Ganz, K. Y. Wolin, A. Elias, H. Krontiras, J. Liu et al. 2015. Results of the exercise and nutrition to enhance recovery and good health for you (ENERGY) trial: a behavioral weight loss intervention in overweight or obese breast cancer survivors. J Clin Oncol Off J Am Soc Clin Oncol. 33(28):3169–76. doi:https://doi.org/10.1200/JCO.2015.61.1095.
- Rosenstock, J., C. Wysham, J. P. Frías, S. Kaneko, C. J. Lee, L. Fernández Landó, H. Mao, X. Cui, C. A. Karanikas, and V. T. Thieu. 2021. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (London, England) 398 (10295):143–55. doi:https://doi.org/10.1016/S0140-6736(21)01324-6.
- Rossato, F. A., K. G. Zecchin, P. G. La Guardia, R. M. Ortega, L. C. Alberici, R. A. P. Costa, R. R. Catharino, E. Graner, R. F. Castilho, and A. E. Vercesi. 2014. Fatty acid synthase inhibitors induce apoptosis in non-tumorigenic melan-a cells associated with inhibition of mitochondrial respiration. PloS ONE 9 (6):e101060. doi:https://doi.org/10.1371/journal.pone.0101060.
- Rother, E. T. 2007. Revisão sistemática X revisão narrativa. Acta Paulista de Enfermagem 20 (2):v–vi. doi:https://doi.org/10.1590/S0103-21002007000200001.
- Sestak, I., W. Distler, J. F. Forbes, M. Dowsett, A. Howell, and J. Cuzick. 2010. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol Off J Am Soc Clin Oncol 28 (21):3411–15. doi:https://doi.org/10.1200/JCO.2009.27.2021.
- Setiawan, V. W., H. P. Yang, M. C. Pike, S. E. McCann, H. Yu, Y.-B. Xiang, A. Wolk, N. Wentzensen, N. S. Weiss, P. M. Webb et al. 2013. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol Off J Am Soc Clin Oncol. 31(20):2607–18. doi:https://doi.org/10.1200/JCO.2012.48.2596.
- Shaikh, H., P. Bradhurst, M. Li Xin, S. Yee Cindy Tan, S. J. Egger, and J. L. Vardy. 2020. Body weight management in overweight and obese breast cancer survivors. Cochrane Database Syst Rev 12 (12):CD012110. doi:https://doi.org/10.1002/14651858.CD012110.pub2.
- Sharretts, J., O. Galescu, S. Gomatam, E. Andraca-Carrera, C. Hampp, and L. Yanoff. 2020. Cancer risk associated with lorcaserin - the FDA’s review of the CAMELLIA-TIMI 61 trial. New Engl J Med 383 (11):1000–02. doi:https://doi.org/10.1056/NEJMp2003873.
- Sheahan, K. H., E. A. Wahlberg, and M. P. Gilbert. 2020. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgraduate Med J 96 (1133):156 LP–61. doi:https://doi.org/10.1136/postgradmedj-2019-137186.
- Sheppard, V. B., J. Hicks, K. Makambi, A. Hurtado-de-Mendoza, W. Demark-Wahnefried, and L. Adams-Campbell. 2016. The feasibility and acceptability of a diet and exercise trial in overweight and obese black breast cancer survivors: the stepping STONE study. Contemp Clin Trials 46 (January):106–13. doi:https://doi.org/10.1016/j.cct.2015.12.005.
- Siegel, R. L., K. D. Miller, and A. Jemal. 2018. Cancer statistics, 2018. CA Cancer J Clinicians 68 (1):7–30. doi:https://doi.org/10.3322/caac.21442.
- Sjöström, L. 2013. Review of the key results from the swedish obese subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Int Med 273 (3):219–34. doi:https://doi.org/10.1111/joim.12012.
- Sjöström, L., C. D. S. Kristina Narbro, K. Karason, H. Larsson, B. Wedel, T. Lystig, T. Lystig, M. Sullivan, C. Bouchard, B. Carlsson et al. 2007. Effects of bariatric surgery on mortality in swedish obese subjects. New Engl J Med. 357(8):741–52. doi:https://doi.org/10.1056/NEJMoa066254.
- Sjöström, L., C. D. S. Anders Gummesson, K. Narbro, M. Peltonen, H. Wedel, C. Bengtsson, C. Bengtsson, C. Bouchard, B. Carlsson, S. Dahlgren et al. 2009. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish obese subjects study): a prospective, controlled intervention trial. Lancet. Oncol. 10(7):653–62. doi:https://doi.org/10.1016/S1470-2045(09)70159-7.
- Sung, H., R. L. Siegel, P. S. Rosenberg, and A. Jemal. 2019. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health 4 (3):e137–47. doi:https://doi.org/10.1016/S2468-2667(18)30267-6.
- Trestini, I., I. Sperduti, A. Caldart, C. Bonaiuto, E. Fiorio, V. Parolin, V. Zambonin, S. Zanelli, D. Tregnago, A. Avancini et al. 2021. Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: a prospective interventional study. Breast (Edinburgh, Scotland). 60(August):6–14. doi:https://doi.org/10.1016/j.breast.2021.08.008.
- von Gruenigen, V., H. Frasure, M. Beth Kavanagh, J. Janata, S. Waggoner, P. Rose, E. Lerner, and K. S. Courneya. 2012. Survivors of uterine cancer empowered by exercise and healthy diet (SUCCEED): a randomized controlled trial. Gynecologic Oncol 125 (3):699–704. doi:https://doi.org/10.1016/j.ygyno.2012.03.042.
- Wilding, J. P. H., R. L. Batterham, S. Calanna, M. Davies, L. F. Van Gaal, I. Lingvay, B. M. McGowan, J. Rosenstock, M. T. D. Tran, T. A. Wadden et al. 2021. Once-weekly semaglutide in adults with overweight or obesity. New Engl J Med. 384(11):989–1002. doi:https://doi.org/10.1056/NEJMoa2032183.
- Wing, R. R., P. Bolin, F. L. Brancati, G. A. Bray, J. M. Clark, M. Coday, R. S. Crow, et al. 2013. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. New Engl J Med 369 (2):145–54. doi:https://doi.org/10.1056/NEJMoa1212914.
- Wysham, W. Z., D. R. Roque, J. Han, L. Zhang, H. Guo, P. A. Gehrig, C. Zhou, and V. L. Bae-Jump. 2016. Effects of fatty acid synthase inhibition by orlistat on proliferation of endometrial cancer cell lines. Targeted Oncol 11 (6):763–69. doi:https://doi.org/10.1007/s11523-016-0442-9.
- Yeh, H.-C., J. P. Bantle, M. Cassidy-Begay, G. Blackburn, G. A. Bray, T. Byers, J. M. Clark, M. Coday, C. Egan, M. A. Espeland et al. 2020. Intensive weight loss intervention and cancer risk in adults with type 2 diabetes: analysis of the look AHEAD randomized clinical trial. Obesity (Silver Spring, Md.). 28(9):1678–86. doi:https://doi.org/10.1002/oby.22936.
- Zhang, K., Y. Luo, H. Dai, and Z. Deng. 2020. Effects of bariatric surgery on cancer risk: evidence from meta-analysis. Obesity Surg 30 (4):1265–72. doi:https://doi.org/10.1007/s11695-019-04368-4.